Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Thiotepa

Thiotepa

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Thiotepa

34 trials tracked of Thiotepa: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 354 citations.

34Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 6 Phase 2 26 Other / NA 2
  1. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 354 cited
  2. Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 223 cited
  3. Phase 3 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Completed · 49 cited
  4. Phase 3 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Completed · 7 cited
  5. Phase 3 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed
  6. Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Completed
Show 28 more trials
  1. Phase 2 Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Completed
  2. Phase 2 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Completed
  3. Phase 2 Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Completed
  4. Phase 2 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed
  5. Phase 2 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed
  6. Phase 2 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Completed
  7. Phase 2 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Completed
  8. Phase 2 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Completed
  9. Phase 2 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed
  10. Phase 2 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed
  11. Phase 2 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed
  12. Phase 2 Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow Completed
  13. Phase 2 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Completed
  14. Phase 2 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed
  15. Phase 2 Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases Completed
  16. Phase 2 Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Completed
  17. Phase 2 CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML Completed
  18. Phase 2 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed
  19. Phase 2 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Completed
  20. Phase 2 New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement Completed
  21. Phase 2 HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies Completed
  22. Phase 2 Randomized Double Cord Blood Transplant Study Completed
  23. Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
  24. Phase 2 Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation Completed
  25. Phase 2 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Completed
  26. Phase 2 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Completed
  27. N/A Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor Completed
  28. N/A High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review of treatment strategies for primary central nervous system lymphoma
Dermatology Sys. Review
Narrative review of treatment strategies for primary central nervous system lymphoma A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
Frontiers May 8, 2026
Autologous hematopoietic stem cell transplantation improves disease-free survival in pediatric extraocular retinoblastoma patients
Pediatrics Cohort
Autologous hematopoietic stem cell transplantation improves disease-free survival in pediatric extraocular retinoblastoma patients Children With Eye Cancer Now Have a New Hope for Survival
This retrospective analysis included 12 children with extraocular retinoblastoma treated with autologous hematopoietic stem cell transplanta…
Children with advanced eye cancer can now achieve long-term survival using their own stem cells, especially if the disease has not reached t…
Frontiers Apr 29, 2026